Novo Nordisk lowers sales and operating profit outlook for 2025
In the first six months of 2025, Novo Nordisk's sales increased by 18% and operating profit increased by 29%, both at CER. Sales growth in the first six months of 2025 was positively impacted by gross-to-net sales adjustments related to prior years, including an adjustment related to the 340B provision of around DKK 3 billion in the second quarter of 2025. Operating profit growth is positively impacted by the ocedurenone impairment in the second quarter of 2024, partially countered by impacts related to the acquisition of the three Catalent manufacturing sites.
Profit and loss
Second quarter 2025
First six months 2025
Sales growth (CER)
18%
18%
Operating profit growth (EBIT) (CER)
40%
29%
Diluted earnings per share (in DKK)
5.96
12.49
Novo Nordisk has updated the full-year outlook for 2025, with sales growth now expected to be 8-14% and operating profit growth expected to be 10-16%, both at CER. Sales and operating profit growth reported in Danish kroner is now expected to be 4 and 7 percentage points lower than at CER, respectively, primarily due to depreciation of the USD/DKK exchange rate1.
Outlook 2025 (CER)
Expectations 29 July
Expectations 7 May
Sales growth
8-14%
13-21%
Operating profit growth (EBIT)
10-16%
16-24%
The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025. This is related to lower growth expectations for Wegovy® in the US obesity market, lower growth expectations for Ozempic® in the US GLP-1 diabetes market, as well as lower-than-expected penetration for Wegovy® in select IO markets.
For Wegovy® in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.
Despite the expiry of the FDA grace period for mass compounding on 22 May 2025, Novo Nordisk market research shows that unsafe and unlawful mass compounding has continued, and that multiple entities continue to market and sell compounded GLP-1s under the false guise of 'personalisation'. Novo Nordisk is pursuing multiple strategies, including litigation, to protect patients from knockoff 'semaglutide' drugs. Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff 'semaglutide' drugs made with illicit or inauthentic foreign active pharmaceutical ingredients.
As unsafe and unlawful mass compounding continues, the Wegovy® penetration within the cash channel has been lower-than-expected. Within this channel, NovoCare® Pharmacy was launched in March 2025. Wegovy® prescriptions via NovoCare® Pharmacy (including TeleHealth collaborations) amount to around 11,000 total weekly prescriptions, in addition to around 20,000 weekly prescriptions in the retail cash channel. Novo Nordisk will continue to invest in the expansion of direct-to-patient initiatives such as NovoCare® Pharmacy and further collaborations with telehealth organisations.
Within the insured channel, despite the initiation of new commercial activities of Wegovy® in the first half of 2025, the sales outlook also reflects lower-than-expected penetration for Wegovy®, mainly due to slower market expansion and competition. Novo Nordisk continues to engage in additional commercial initiatives and expects a regulatory decision around the Wegovy® MASH indication during the second half of 2025. Moreover, Novo Nordisk continues to expect a positive contribution from changes to the CVS national template formulary effective 1 July 2025, where Wegovy® is now the only GLP-1 medicine covered for obesity.
For Ozempic®, the updated outlook is negatively impacted by competition in the US. Novo Nordisk continues to invest in commercial activities and label updates towards driving further market penetration of Ozempic®.
Finally, while IO Wegovy® sales are growing at high rates and launches are progressing, the sales outlook reflects lower-than-expected penetration for Wegovy® in select IO markets due to slower market expansion and competition. With around 1 billion people living with obesity globally and only a few million on treatment, the outlook reflects a continued global rollout of Wegovy® to more markets.
The updated expectation for operating profit growth reflects the lower sales growth outlook, partially countered by reduced spending. A negative mid-single-digit operating profit growth impact related to the acquisition of the three former Catalent manufacturing sites remains included in the guidance.
Novo Nordisk now expects financial items (net) for 2025 to amount to a gain of around DKK 3 billion. This is mainly driven by expected gains on hedged currencies, primarily the US dollar, partially offset by interest expenses related to funding of the debt-financed Catalent transaction.
Finally, the free cash flow is now expected to be DKK 35-45 billion, reflecting the lower-than-planned expected sales growth, mainly driven by lower volume growth of GLP-1-based treatments in the US and related cash flow implications amplified by the US gross-to-net system.
Novo Nordisk's full disclosure of the financial results for the first six months of 2025 will be published on 6 August 2025, where more information will be available.
The above expectations are based on additional assumptions, including assumptions described on pages 14 and 15 of the Financial report for the first three months of 2025 (Company Announcement No 14/2025).
The forward-looking statements on page 23 in the Financial report for the first three months of 2025 (Company Announcement No 14/2025) also apply to this company announcement.
Conference call
Novo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of novonordisk.com.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown +45 3079 9289abmo@novonordisk.com
Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com
Frederik Taylor Pitter (US)+1 609 613 0568 fptr@novonordisk.com
Publication of inside information pursuant to Market Abuse Regulation, Article 17
1 Based on exchange rates of 23 July 2025 with e.g. a USD/DKK spot rate of 635. Full currency overview to be released as part of Novo Nordisk's full disclosure of the financial results on 6 August 2025
Company announcement No 18 / 2025
Attachment
CA250729-Q2-Financial-Outlook
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Nonwoven Fabrics Market worth $72.21 billion by 2030, at a CAGR of 5.7%, says MarketsandMarkets™
Delray Beach, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) — The Nonwoven Fabrics Market is anticipated to grow from USD 54.73 billion in 2025 to USD 72.21 billion in 2030, at a CAGR of 5.7%, as per the recent study by MarketsandMarkets™. The nonwoven fabric market is experiencing robust growth, driven by the escalating demand for sanitary, reliable, and high-performance materials across various sectors, including automotive, filtration, medical, and hygiene. Nonwoven materials are characterized by their lightweight composition, superior absorbency, breathability, and cost-effectiveness, making them ideally suited for protective and disposable applications. Their effectiveness, zero maintenance requirements, and consistent quality address the evolving needs of both consumers and industry professionals. These factors contribute to the success of nonwovens as a preferred alternative for manufacturers seeking high-performance, long-lasting, and contamination-free solutions, ranging from automotive insulation to surgical masks. The increasing emphasis on sustainability is catalyzing the advancement of biodegradable and eco-friendly nonwoven fabrics, fundamentally transforming product manufacturing across the hygiene, medical, and packaging sectors. These sustainable nonwovens are produced from materials such as polylactic acid (PLA), bamboo fibers, and other natural or recycled resources. They deliver superior durability, lightweight characteristics, and skin compatibility while significantly minimizing environmental impact. The biodegradable wipes and packaging solutions market has gained considerable traction in daily applications. Leading companies, including Freudenberg Group and Suominen Corporation, are at the forefront of providing sustainable nonwovens that align with global objectives for waste reduction and the promotion of a circular economy. Download PDF Brochure: Browse in-depth TOC on 'Nonwoven Fabrics Market' 383 – Market Data Tables 57 – Figures 320 – Pages List of Key Players in Nonwoven Fabrics Market: Berry Global Inc. (US) Freudenberg Group (Germany) Ahlstrom (Finland) Kimberly-Clark Worldwide, Inc. (US) Fitesa S.A. and Affiliates (Brazil) DuPont (US) Toray Industries, Inc. (Japan) Alkegen (US) Avgol Industries 1953 Ltd (Israel) Zhejiang Kingsafe Hygiene Material Technology Co.,Ltd (China) Suominen Corporation (Finland) Johns Manville (US) Drivers, Opportunities and Challenges in Nonwoven Fabrics Market: Drivers: Surging demand in hygiene and medical applications Restraint: Regulatory pressures restricting use of plastic-based nonwovens Opportunity: Growing demand for advanced filtration in air and water purification applications Challenge: Requirement for high investments in recycling technology Get Sample Pages: Key Findings of the Study: Dry laid segment accounted for second-largest share of nonwoven fabric market in 2024 Building & construction segment accounted for second-largest share of nonwoven fabrics market in 2024 North America held second-largest share of nonwoven fabrics market in 2024 By technology, the spunbond segment holds the largest market share due to its efficiency, cost-effectiveness, and versatility across various applications. Spunbond technology facilitates the continuous production of consistent, durable, and lightweight fabrics, making it ideal for use in hygienic products, medical and healthcare supplies, agricultural coverings, and packaging solutions. The spunbond process is characterized by rapid production capabilities, minimal waste generation, and the adaptability to integrate biodegradable polymers. As demand for disposable and sustainable nonwoven products continues to rise, manufacturers are increasingly investing in upgraded spunbond production lines, utilizing bio-based raw materials, and developing multi-layer structures to enhance performance. Based on end-use industry, hygiene is currently the fastest-growing segment in the market, driven by an escalating demand for high-absorbency, skin-friendly, and disposable materials essential to the hygiene industry. Nonwoven fabrics are particularly well-suited for applications in this sector, including baby diapers, feminine hygiene products, adult incontinence solutions, and personal wipes. Their attributes, such as breathability, softness, and superior fluid management capabilities, make them ideal for these products. Nonwoven fabrics deliver the necessary comfort and performance and adhere to stringent hygiene and safety standards. Get Customization on this Report: In 2024, North America emerged as the second-largest market for nonwoven fabrics, driven primarily by robust demand from the healthcare, hygiene, and automotive sectors. The region boasts a well-established manufacturing infrastructure and leads in technological advancements in nonwoven production. Furthermore, it adheres to stringent regulatory standards that promote the creation of high-performance and sustainable nonwoven products. North America offers multiple entry points for businesses, underpinned by ongoing investments in product development and capacity expansion from key players in the nonwoven industry. The heightened consumer focus on hygiene—exacerbated by the COVID-19 pandemic—has catalyzed increased investment and adoption of single-use, disposable nonwovens across various applications. The US market for nonwoven fabrics is experiencing steady growth, driven by strong demand across the hygiene, medical, filtration, and automotive industries. Key factors contributing to this expansion include advancements in nonwoven technology, a preference for lightweight and high-performance materials, and an increased reliance on disposable and contamination-free products. The presence of leading manufacturers and a well-established industrial base further drives this market. Additionally, high investments in healthcare infrastructure and bioproducts production are facilitating broader acceptance of nonwoven fabrics across diverse applications. The use of automation and the Internet of Things (IoT) presents substantial growth prospects for the nonwoven fabrics market by enhancing efficiency, precision, and sustainability across various sectors. Modern nonwoven production systems are evolving into more intelligent frameworks, characterized by real-time monitoring and predictive maintenance, significantly decreasing reliance on continuous human oversight. IoT sensors and AI-driven tools facilitate the early detection of issues such as material defects, machine deterioration, and production inefficiencies, enabling prompt interventions and minimizing downtime. Manufacturers can capitalize on these advancements by providing digitally integrated nonwoven solutions, particularly for critical applications, including medical products, filtration systems, and hygiene products. Berry Global Inc. (US) is a leading manufacturer and supplier of innovative, environmentally friendly packaging solutions and engineered materials, serving a range of markets, including the healthcare, hygiene, food and beverage, beauty and personal care, construction, filtration, homecare, and specialty sectors. The company's operations are divided into four reporting segments: Consumer Packaging International, Consumer Packaging North America, Flexibles, and Health, Hygiene & Specialties Freudenberg Group (Germany) is a worldwide technology company committed to providing intelligent solutions that drive customer success and foster sustainable development in various industries. The group provides a broad portfolio of products, including seals and nonwovens, consumer products, lubricants, and IT services. The company's operations are structured into several business segments: Seals and Vibration Control Technology, Technical Textiles and Filtration, Cleaning Technologies and Products, and Specialties, each supported by specialist business groups. Browse Adjacent Markets Yarns, Fabric and Textile Market Research Reports & Consulting Related Reports: Polyethylene Furanoate (PEF) Market Data Center Cooling Market Elevators & Escalators Market Glass Substrate Market Centrifuge Market Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
4 hours ago
- Yahoo
Weekly Picks: ASML's Selloff Explained, WH's Global Expansion, and NVO's Market Mispricing
Each week our analysts hand pick their favourite Narratives from the community ( ). This week's picks cover: 📈 Why now might be an opportune time to consider ASML . 🏨 How Wyndham Hotels' loyalty revenue and global expansion are driving growth. 💊 Why Novo Nordisk's risk/reward case is better than it seems. 💡 Why we like it: This narrative is a tight, well-balanced pitch that blends technical context with market timing. Instead of ignoring the selloff, they lean into it, framing the stock dip as a rare opportunity in an otherwise solid long-term story. We think the narrative strikes the right tone of measured, informed, and actionable. 💡 Why we like it: This is a refreshingly boots-on-the-ground narrative that builds from personal experience to a full investment case. Zwfis weaves operational context, recent earnings, and valuation math into a compelling long-term outlook, while also highlighting under-appreciated levers like loyalty-driven ancillary revenue. It's personal, well-researched, and has plenty of conviction. 💡 Why we like it: We love a classic contrarian setup. Here bactrian makes the case that a best-in-class compounder has been marked down on fears that appear priced for disaster rather than a cyclical reset. The narrative does a great job breaking down both the bear case (guidance cut, semaglutide saturation, policy risk) and why it's likely overdone, given Novo's world-class margins, strong pipeline, and low multiple. The sum-of-the-parts logic and reset expectations create a compelling upside case. What's next? 🔔 Know when to act: Set the narrative valuations as your own fair value to know when to buy, hold or sell the stock. 🤔 Get answers: Ask the author any questions in the comments section. Feel free to like as well to support their work. ✨ Discover more Narratives: There are hundreds of other insightful stock narratives on our Community page . ✍️ Build an audience: Have your narrative seen by millions of investors, simply meet our Featuring criteria to go into the running! Disclaimer Simply Wall St has no position in any of the companies mentioned. These narratives are general in nature and explore scenarios and estimates created by the authors. These narratives do not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimate's are estimations only, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Simply Wall St analyst Michael Paige and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Yahoo
4 hours ago
- Yahoo
Disney, Novo, & McDonald's earnings; Fed speak: What to Watch
Market Domination Overtime host Josh Lipton takes a look at the top stories for investors to watch on Wednesday, Aug. 6. Novo Nordisk (NVO), Disney (DIS), McDonald's (MCD), Uber (UBER), and Shopify (SHOP) will report earnings results in the morning. Lyft (LYFT) will report in the afternoon. Federal Reserve governor Lisa Cook and Boston Fed president Susan Collins will deliver remarks. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime. Related videos 2.6 million people to be stung by savings tax Labour urged to come clean on exit tax Why Australian retirees are seven times richer than us This superb FTSE 100 passive income stock now generates a stellar 8.1% dividend yield! Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
